BioMarin impresses with Phase II dwarfism drug
BioMarin Pharmaceuticals has raised expectations for its dwarfism product BMN-111 (vosoritide) on the back of strong Phase II data.
BioMarin Pharmaceuticals has raised expectations for its dwarfism product BMN-111 (vosoritide) on the back of strong Phase II data.